OR WAIT null SECS
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 9, 2021.
Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.
Click the image to view the story.
Methotrexate has been the mainstay treatment for mild to moderate arthritis for many years, and the recent update to the American College of Rheumatology Guidelines on the Management of Rheumatoid Arthritis aims to maximize the use of methotrexate before advancing to a biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD). With this in mind, it is important to be up-to-speed on initiating methotrexate in patients with rheumatoid arthritis. Test your knowledge with this quiz.
Click the image to view the story.
Chronic pain and functional limitations, along with these academic and social difficulties, are directly related to mental health complaints. Therefore, adolescents with rheumatic diseases are at a higher risk for developing mental illness.
Click the image to view the story.
Patients with autoimmune inflammatory rheumatic diseases had an increased risk of testing positive for SARS-CoV-2 and worse clinical outcomes of COVID-19, including death, although disease-modifying antirheumatic drugs (DMARDs) did not increase the risk of these outcomes.
Click the image to view the story.